The DOI matches its Crossref record; 133 of the 134 references it cites were found in a registry or an index.
Chylomicronaemia–current diagnosis and future therapies
Abstract
This Review discusses new developments in understanding the basis of chylomicronaemia--a challenging metabolic disorder for which there is an unmet clinical need. Chylomicronaemia presents in two distinct primary forms. The first form is very rare monogenic early-onset chylomicronaemia, which presents in childhood or adolescence and is often caused by homozygous mutations in the gene encoding lipoprotein lipase (LPL), its cofactors apolipoprotein C-II or apolipoprotein A-V, the LPL chaperone lipase maturation factor 1 or glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1. The second form, polygenic late-onset chylomicronaemia, which is caused by an accumulation of several genetic variants, can be exacerbated by secondary factors, such as poor diet, obesity, alcohol intake and uncontrolled type 1 or type 2 diabetes mellitus, and is more common than early-onset chylomicronaemia. Both forms of chylomicronaemia are associated with an increased risk of life-threatening pancreatitis; the polygenic form might also be associated with an increased risk of cardiovascular disease. Treatment of chylomicronaemia focuses on restriction of dietary fat and control of secondary factors, as available pharmacological therapies are only minimally effective. Emerging therapies that might prove more effective than existing agents include LPL gene therapy, inhibition of microsomal triglyceride transfer protein and diacylglycerol O-acyltransferase 1, and interference with the production and secretion of apoC-III and angiopoietin-like protein 3.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“complete apo C-II deficiency accounts for ∼2% of all FCS cases.93”
From Clinical review on triglycerides (2020) · cites this paper as [93]
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [6]
In the citing paper
“Effectiveness of omega-3 fatty acids, routinely used in pharmacologic doses for treatment of severe HTG, has been inconsistent in patients with FCS.3,[16][17][18]20”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [3]
In the citing paper
“Even when patients adhere to the very-low-fat diet and are monitored by a registered dietitian nutritionist (RDN), TG levels may remain dangerously high.3,20,21”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [3]
In the citing paper
“Of note, prescription omega-3 fatty acids (up to 4 grams per day) have shown inconsistent effectiveness as a treatment for HTG in patients with FCS.3,[16][17][18][19]”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [3]
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Acute pancreatitis: value of CT in establishing prognosis.
Balthazar, E. J., Robinson, D. L., Megibow, A. J., & Ranson, J. H. C. (1990) · Radiology · doi:10.1148/radiology.174.2.2296641 · Cited by 1,682
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Whitcomb, D. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp054958 · Cited by 747
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Self-citationHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationHypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624
Self-citationPrakash, T. P., Graham, M., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 588
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Self-citationA Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 529
Self-citationApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274
Apolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Moulin, P., Dufour, R., Averna, M., Arca, M., Cefalù, A. B., Noto, D., D'Erasmo, L., Di Costanzo, A., Marçais, C., Alvarez-Sala Walther, L. A., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.814 · Cited by 247
Genetics of hypertriglyceridemia
Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244
Self-citation2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Severe hypertriglyceridemia is primarily polygenic
Dron, J. S., Wang, J., Cao, H., McIntyre, A. D., Iacocca, M. A., Menard, J. R., Movsesyan, I., Malloy, M. J., Pullinger, C. R., Kane, J. P., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.10.006 · Cited by 222
Self-citationXiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Self-citationHegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204
Self-citationRole of lipoprotein lipase in lipid metabolism
Olivecrona, G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000297 · Cited by 189
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409368 · Cited by 178
Self-citationNewman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 182
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Gaudet, D., Pall, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. M. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0959 · Cited by 172
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Self-citationClinical and biochemical features of different molecular etiologies of familial chylomicronemia
Hegele, R. A., Berberich, A. J., Ban, M. R., Wang, J., Digenio, A., Alexander, V. J., D'Erasmo, L., Arca, M., Jones, A., Bruckert, E., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.03.093 · Cited by 165
Self-citationGenetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148
Self-citationMechanisms linking hypertriglyceridemia to acute pancreatitis
Kiss, L., Fűr, G. M., Pisipati, S., Rajalingamgari, P., Ewald, N., Singh, V. P., & Rakonczay, Z. (2023) · Acta Physiologica · doi:10.1111/apha.13916 · Cited by 151
Familial chylomicronemia syndrome: an under‐recognized cause of severe hypertriglyceridaemia
Baass, A., Paquette, M., Bernard, S., & Hegele, R. A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13016 · Cited by 144
Self-citationDiagnostic algorithm for familial chylomicronemia syndrome
Stroes, E., Moulin, P., Parhofer, K. G., Rebours, V., Löhr, J.-M., & Averna, M. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.002 · Cited by 130
Chait, A., & Eckel, R. H. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0203 · Cited by 128
Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span
Williams, L., Rhodes, K. S., Karmally, W., Welstead, L. A., Alexander, L., & Sutton, L. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.04.010 · Cited by 125
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
A Comprehensive Update on the Chylomicronemia Syndrome
Goldberg, R. B., & Chait, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.593931 · Cited by 125
Paquette, M., Bernard, S., Hegele, R. A., & Baass, A. W. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.019 · Cited by 117
Self-citationGenetics of Triglycerides and the Risk of Atherosclerosis
Dron, J. S., & Hegele, R. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0667-9 · Cited by 114
Self-citationYang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103
Mysling, S., Kristensen, K. K., Larsson, M., Beigneux, A. P., Gårdsvoll, H., Fong, L. G., Bensadoun, A., Jørgensen, T. J. D., Young, S. G., & Ploug, M. (2016) · eLife · doi:10.7554/elife.12095 · Cited by 98
Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists
Falko, J. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0157 · Cited by 93
Dron, J. S., Wang, J., McIntyre, A. D., Iacocca, M. A., Robinson, J. F., Ban, M. R., Cao, H., & Hegele, R. A. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0669-2 · Cited by 93
Self-citationDyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 88
Self-citationCharacterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
Blom, D. J., O'Dea, L., Digenio, A., Alexander, V. J., Karwatowska-Prokopczuk, E., Williams, K. R., Hemphill, L., Muñiz-Grijalvo, O., Santos, R. D., Baum, S., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.05.013 · Cited by 82
Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics
Julve, J., Martín-Campos, J. M., Escolá‐Gil, J. C., & Blanco‐Vaca, F. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.004 · Cited by 94
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study
Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Roeters van Lennep, J., Crowson, C., & Witztum, J. L. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.04.009 · Cited by 82
Kristensen, K. K., Leth-Espensen, K. Z., Mertens, H. D. T., Birrane, G., Meiyappan, M., Olivecrona, G., Jørgensen, T. J. D., Young, S. G., & Ploug, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920202117 · Cited by 72
Rabacchi, C., Pisciotta, L., Cefalu, A. B., Noto, D., Fresa, R., Tarugi, P., Averna, M. R., Bertolini, S., & Calandra, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.815 · Cited by 74
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)
Averna, M., Cefalu, A. B., Casula, M., Noto, D., Arca, M., Bertolini, S., Calandra, S., Catapano, A. L., Tarugi, P., Arca, M., et al. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.07.001 · Cited by 72
Hypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes
D’Erasmo, L., Costanzo, A. D., Cassandra, F., Minicocci, I., Polito, L., Montali, A., Ceci, F., & Arca, M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313401 · Cited by 69
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200325 · Cited by 71
Self-citationConservative management in hypertriglyceridemia-associated pancreatitis
Berberich, A. J., Ziada, A., Zou, G. Y., & Hegele, R. A. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12925 · Cited by 67
Self-citationDyslipidemia in Pediatric Type 2 Diabetes Mellitus
Sunil, B., & Ashraf, A. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01336-6 · Cited by 65
A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase
Kristensen, K. K., Midtgaard, S. R., Mysling, S., Kovrov, O., Hansen, L. B., Skar‐Gislinge, N., Beigneux, A. P., Kragelund, B. B., Olivecrona, G., Young, S. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806774115 · Cited by 68
O'Dea, L. S. L., MacDougall, J., Alexander, V. J., DIGENIO, A. G., Hubbard, B., Arca, M., Moriarty, P. M., Kastelein, J. J. P., Bruckert, É., Soran, H., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00214 · Cited by 64
Self-citationFamilial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60
Self-citationPosicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021
Izar, M. C. D. O., Lottenberg, A. M., Giraldez, V. Z. R., Santos, R. D., Machado, R. M., Bertolami, A., Assad, M. H. V., Saraiva, J. F. K., Faludi, A. Á., Moreira, A. S. B., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201340 · Cited by 78
The polygenic nature of mild-to-moderate hypertriglyceridemia
Dron, J. S., Wang, J., McIntyre, A. D., Cao, H., & Hegele, R. A. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.003 · Cited by 56
Self-citationThe burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study
Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Crowson, C., & Witztum, J. L. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1311786 · Cited by 54
Apolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A. T., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 58
Arca, M., Borghi, C., Pontremoli, R., Ferrari, G. M. D., Colivicchi, F., Desideri, G., & Temporelli, P. L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.001 · Cited by 54
Kupikowska-Stobba, B., Niu, H., Klojdová, I., Agregán, R., Lorenzo, J. M., & Kasprzak, M. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.142151 · Cited by 57
Basu, D., & Bornfeldt, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00504 · Cited by 51
Arca, M., Hsieh, A., Soran, H., Rosenblit, P., O’Dea, L., & Stevenson, M. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1487290 · Cited by 49
Chait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 50
Leth-Espensen, K. Z., Kristensen, K. K., Kumari, A., Winther, A.-M. L., Young, S. G., Jørgensen, T. J. D., & Ploug, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026650118 · Cited by 48
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01525-5 · Cited by 50
Extreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence
Chyzhyk, V., Kozmic, S., Brown, A. S., Hudgins, L. C., Starc, T. J., Davila, A. D., Blevins, T. C., Diffenderfer, M. R., He, L., Geller, A. S., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.09.007 · Cited by 44
Self-citationChaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 47
Chyzhyk, V., & Brown, A. S. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.001 · Cited by 46
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Self-citationCurrent Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 44
Bashir, B., Ho, J. H., Downie, P., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 49
Ueda, M., Dunbar, R. L., Wolska, A. T., Sikora, T. U., Escobar, M. D. R., Seliktar, N., deGoma, E. M., DerOhannessian, S. L., Morrell, L., McIntyre, A. D., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3903 · Cited by 44
Self-citationFamilial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 44
Gutgsell, A. R., Ghodge, S. V., Bowers, A. A., & Neher, S. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005932 · Cited by 41
Hegele, R. A., Ahmad, Z., Ashraf, A. P., Baldassarra, A., Brown, A. S., Chait, A., Freedman, S. D., Kohn, B., Miller, M. J., Patni, N., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.008 · Cited by 40
Self-citationGenetics of hypertriglyceridemia and atherosclerosis
Gill, P. K., Dron, J. S., & Hegele, R. A. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000839 · Cited by 39
Self-citationThe role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 40
Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis
Abu‐El‐Haija, M. A., Gukovskaya, A. S., Andersen, D. K., Gardner, T. B., Hegyi, P. J., Pandol, S. J., Papachristou, G. I., Saluja, A. K., Singh, V. K., Uç, A., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001175 · Cited by 38
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Paquette, M., Amyot, J., Fantino, M., Baass, A. W., & Bernard, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab360 · Cited by 39
Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 37
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
Self-citationA Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II
Meyers, N. L., Larsson, M., Olivecrona, G., & SMALL, D. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629865 · Cited by 34
Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
Alfonsi, J., Hegele, R. A., & Gryn, S. E. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0573-6 · Cited by 35
Self-citationChylomicronemia syndrome: Familial or not?
Warden, B. A., Minnier, J., Duell, P. B., Fazio, S., & Shapiro, M. D. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.01.014 · Cited by 34
The burden of familial chylomicronemia syndrome from the patients’ perspective
Gelrud, A., Williams, K. R., Hsieh, A., Gwosdow, A. R., Gilstrap, A., & Brown, A. S. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1372193 · Cited by 33
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 33
Paragh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 35
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Self-citationThe Evolving Story of Multifactorial Chylomicronemia Syndrome
Paquette, M., & Bernard, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.886266 · Cited by 31
Pediatric Dyslipidemia—Beyond Familial Hypercholesterolemia
Lazarte, J., & Hegele, R. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.020 · Cited by 32
Self-citationThe longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants
Perera, S. D., Wang, J., McIntyre, A. D., Dron, J. S., & Hegele, R. A. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.007 · Cited by 31
Self-citationLoss-of-Function CREB3L3 Variants in Patients With Severe Hypertriglyceridemia
Dron, J. S., Dilliott, A. A., Lawson, A., McIntyre, A. D., Davis, B. D., Wang, J., Cao, H., Movsesyan, I., Malloy, M. J., Pullinger, C. R., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314168 · Cited by 32
Self-citationLomitapide for the treatment of hypertriglyceridemia
Berberich, A. J., & Hegele, R. A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254187 · Cited by 29
Self-citationThe burden of familial chylomicronemia syndrome in Canadian patients
Gaudet, D., Stevenson, M. T., Komari, N., Trentin, G. A., Crowson, C., Hadker, N., & Bernard, S. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01302-x · Cited by 29
A new phenotypic classification system for dyslipidemias based on the standard lipid panel
Sampson, M. L., Ballout, R. A., Soffer, D. E., Wolska, A. T., Wilson, S. R., Meeusen, J. W., Donato, L. J., Fatica, E. M., Otvos, J. D., Brinton, E. A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01585-8 · Cited by 34
Berberich, A. J., Ouédraogo, A. M., Shariff, S. Z., Hegele, R. A., & Clemens, K. K. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01517-6 · Cited by 28
Self-citationCefalu, A. B., Spina, R., Noto, D., Ingrassia, V., Valenti, V., Giammanco, A., Fayer, F., Misiano, G., Cocorullo, G., Scrimali, C., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.003 · Cited by 26
Pedersen, S. B., Varbo, A., Langsted, A., & Nordestgaard, B. G. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12713 · Cited by 26
Hassanloo, J., Béland‐Bonenfant, S., Paquette, M., Baass, A. W., & Bernard, S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.064 · Cited by 26
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 27
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 25
Self-citationGarg, A., Garg, V., Hegele, R. A., & Lewis, G. F. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30156-1 · Cited by 24
Self-citationD’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 24
Metadata
- Authors
- Brahm, A. J., & Hegele, R. A.
- Affiliations
- Western University (CA)
- Corresponding author
- Hegele, Robert A.
- ORCID
- Hegele, Robert A.
- Venue
- Nature Reviews Endocrinology
- Published
- 2015-03-03
- Volume
- 11
- Issue
- 6
- Pages
- 352-362
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W2067802636
- Cited by
- 356
- References
- 134
- Citations by year
- 2026: 32 · 2025: 26 · 2024: 37 · 2023: 28 · 2022: 35 · 2021: 33 · 2020: 43 · 2019: 30 · 2018: 36 · 2017: 25 · 2016: 20 · 2015: 9
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‑79533), MOP13430)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- lipoprotein lipase deficiency, apolipoprotein C-II, apolipoprotein A-V, genetic basis, pancreatitis risk, cardiovascular risk, dietary fat restriction, apolipoprotein C-III, ANGPTL3, new drugs
- MeSH terms
- Hypolipidemic Agents, Benzimidazoles, Diet Therapy, Humans, Hyperlipoproteinemia Type V, Hyperlipoproteinemia Type I, Niacin, Plasma Exchange, Plasmapheresis, Genetic Therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
